Evidence map›Paper›PMID 36609092›Full record

ArticleThe Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation2023

Utilization of COVID-19 positive donors for Heart transplantation and associated short-term outcomes.

Ersilia M DeFilippis, Brian Wayda, Anuradha Lala, Michael M Givertz, Kiran K Khush

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Early Outcomes of Adult Heart Transplantation From COVID-19 Infected Donors.Journal of the American College of Cardiology · 2023
    Article
  5. Heart Transplant: Challenge Accepted.Journal of the American College of Cardiology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 5 institutions in 1 country.

Ersilia M DeFilippisDivision of Cardiology, Columbia University Irving Medical Center, New York, New York.
Brian WaydaDivision of Cardiovascular Medicine, Stanford University School of Medicine, Palo Alto, California.
Anuradha LalaDivision of Cardiology, Mount Sinai Health System, New York, New York.
Michael M GivertzDivision of Cardiology, Brigham and Women's Hospital, Boston, Massachsetts.
Kiran K KhushDivision of Cardiovascular Medicine, Stanford University School of Medicine, Palo Alto, California. Electronic address: kiran@stanford.edu.
Brigham and Women's Hospital · USColumbia University Irving Medical Center · USMount Sinai Health System · USPalo Alto University · USStanford University · US

Funding

Evidence Based Evaluation and Acceptance of Donor Hearts for TransplantationR01HL125303 · NHLBI · STANFORD UNIVERSITY · PI KHUSH, KIRAN KAUR · 2015 to 2019
$3.0M
Narrowing the gap between supply and demand in heart transplantationF32HL154750 · NHLBI · STANFORD UNIVERSITY · PI WAYDA, BRIAN · 2022 to 2024
$165k
NHLBI NIH HHS F32 HL154750NHLBI NIH HHS R01 HL125303
6 · The paper itself

Abstract

backgroundThe safety and efficacy of using COVID-19 positive donors in heart transplantation (HT) are increasingly relevant, but not well established. The present study evaluated the characteristics and utilization of such donors and associated post-HT outcomes.

methodsAll adult (≥18 years old) potential donors and HT recipients in the United States from April 21, 2020 to March 31, 2022 were included. Donor COVID-19 status was defined by the presence (or absence) of any positive test within 21 days of organ recovery. Donor and recipient characteristics and post-HT outcomes, including a primary composite of death, graft failure, and re-transplantation, were compared by donor COVID-19 status.

resultsOf 967 COVID-19(+) potential donors, 19.3% (n = 187) were used for HT compared to 26.7% (n = 6277) of COVID-19(-) donors (p < 0.001). Transplanted COVID-19(+) vs COVID-19(-) donors were younger, but otherwise were similar. Recipients of hearts from COVID-19+ vs COVID-19(-) donors less frequently received pre-HT inotropes (24.1% vs 31.7%, p = 0.023) and ventricular assist device therapy (29.7% vs 36.8%, p = 0.040). There were no significant differences in any post-HT outcome by donor COVID-19 status, including the primary composite outcome at 90 days (5.4% vs 5.6%, p = 0.91). Among COVID-19(+) donors, the presence of a subsequent negative test prior to transplant was not associated with posttransplant outcomes.

conclusionsOur results suggest that carefully selected COVID-19 positive donors may be used for HT with no difference in short-term post-transplant outcomes. Additional data regarding donor and recipient treatments and impact of vaccination should be collected to better inform our use of organs from COVID(+) donors.

Indexed as

COVID-19Heart TransplantationAdolescentAdultDonor SelectionHeartHumansTissue DonorsTreatment OutcomeUnited Statescoronavirus-19donor selectionheart transplantationinfectionrejectionsurvival

Identifiers

PMID36609092
PMCPMC10121733
OpenAlexW4312052733

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.